Prognostic variables and nomograms for renal cell carcinoma

International Journal of Urology

Volumn 18, Issue 1, 2011, Pages 20-31

  Flanigan, Robert C ^a   Polcari, Anthony J ^a   Hugen, Cory M ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Carcinoma; Nomogram; Predictor; Prognosis; Renal cell; Tumor

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN;

BLOOD CELL COUNT; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CLINICAL FEATURE; ERYTHROCYTE SEDIMENTATION RATE; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; KARAKIEWICZ NOMOGRAM; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; NOMOGRAM; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; TUMOR VOLUME;

AGE FACTORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY; KIDNEY NEOPLASMS; NOMOGRAMS;

EID: 78650648460     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02642.x     Document Type: Review

References (121)

1. Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J. Urol. 2010; 28: 247-52.
2. Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur. J. Cancer Prev. 2002; 11: 171-8.
3. Levi F, Ferlay J, Galeone C et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 2008; 101: 949-58.
4. Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur. Urol. 2008; 54: 133-40.
5. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008; 14: 288-301.
6. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J. Urol. 2005; 173: 1853-62.
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009; 59: 225-49.
8. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998; 51: 203-5.
9. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer 2004; 100: 738-45.
10. Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer 2010; 116: 347-54.
11. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J. Urol. 2000; 163: 426-30.
12. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology 2000; 56: 58-62.
13. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J. Urol. 2003; 170 (6 Pt 1): 2217-20.
14. Thompson RH, Kurta JM, Kaag M et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J. Urol. 2009; 181: 2033-6.
15. Lane BR, Babineau D, Kattan MW et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J. Urol. 2007; 178: 429-34.
16. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J. Urol. 2006; 175: 425-31.
17. Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH, Bilous AM. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 2002; 94: 658-64.
18. Zisman A, Pantuck AJ, Dorey F et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J. Clin. Oncol. 2002; 20: 1368-74.
19. Targonski PV, Frank W, Stuhldreher D, Guinan PD. Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases stage 1 and stage 2 patients. J. Urol. 1994; 152 (5 Pt 1): 1389-92.
20. Russo P, Jang TL, Pettus JA et al. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 2008; 113: 84-96.
21. Zisman A, Pantuck AJ, Chao D et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm better correlates with clinical outcome. J. Urol. 2001; 166: 54-8.
22. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 2002; 59: 532-7.
23. Ficarra V, Guille F, Schips L et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 2005; 104: 2116-23.
24. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J. Urol. 1999; 162: 1930-3.
25. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J. Urol. 2004; 171: 1066-70.
26. Patard JJ, Shvarts O, Lam JS et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J. Urol. 2004; 171 (6 Pt 1): 2181-5.
27. Huang WC, Levey AS, Serio AM et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006; 7: 735-40.
28. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
29. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors - is there a difference in mortality and cardiovascular outcomes? J. Urol. 2009; 181: 55-61.
30. Campbell SC, Novick AC, Belldegrun A et al. Guideline for management of the clinical T1 renal mass. J. Urol. 2009; 182: 1271-9.
31. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 2003; 27: 612-24.
32. Aydin H, Zhou M. The changing face of renal cell carcinoma pathology. Curr. Oncol. Rep. 2008; 10: 235-44.
33. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol. 2005; 23: 2763-71.
34. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000; 89: 604-14.
35. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology 2007; 39: 459-65.
36. Leibovich BC, Lohse CM, Crispen PL et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol. 2010; 183: 1309-15.
37. Gong K, Zhang N, He Z, Zhou L, Lin G, Na Y. Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases. J. Cancer Res. Clin. Oncol. 2008; 134: 433-7.
38. Nassir A, Jollimore J, Gupta R, Bell D, Norman R. Multilocular cystic renal cell carcinoma: a series of 12 cases and review of the literature. Urology 2002; 60: 421-7.
39. Suzigan S, Lopez-Beltran A, Montironi R et al. Multilocular cystic renal cell carcinoma a report of 45 cases of a kidney tumor of low malignant potential. Am. J. Clin. Pathol. 2006; 125: 217-22.
40. Webster WS, Thompson RH, Cheville JC, Lohse CM, Blute ML, Leibovich BC. Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma. Urology 2007; 70: 900-4.
41. Amin MB, Amin MB, Tamboli P et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. 2002; 26: 281-91.
42. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum. Pathol. 2001; 32: 590-5.
43. Antonelli A, Tardanico R, Balzarini P et al. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet. Cytogenet. 2010; 199: 128-33.
44. Klatte T, Pantuck AJ, Said JW et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin. Cancer Res. 2009; 15: 1162-9.
45. Pignot G, Elie C, Conquy S et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69: 230-5.
46. Lam JS, Klatte T, Kim HL et al. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit. Rev. Oncol. Hematol. 2008; 65: 235-62.
47. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J. Urol. 1995; 154: 964-7.
48. Tickoo SK, Gopalan A. Pathologic features of renal cortical tumors. Urol. Clin. North Am. 2008; 35: 551-61.
49. Mancini V, Battaglia M, Ditonno P et al. Current insights in renal cell cancer pathology. Urol. Oncol. 2008; 26: 225-38.
50. Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin. Diagn. Pathol. 1998; 15: 54-67.
51. Avery RA, Harris JE, Davis CJ Jr, Borgaonkar DS, Byrd JC, Weiss RB. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer 1996; 78: 128-32.
52. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology 2010; 42: 369-73.
53. Klatte T, Anterasian C, Said JW et al. Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J. Urol. 2010; 183: 2143-7.
54. Sika-Paotonu D, Bethwaite PB, McCredie MR, William Jordan T, Delahunt B. Nucleolar grade but not fuhrman grade is applicable to papillary renal cell carcinoma. Am. J. Surg. Pathol. 2006; 30: 1091-6.
55. Delahunt B, Sika-Paotonu D, Bethwaite PB et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am. J. Surg. Pathol. 2007; 31: 957-60.
56. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur. Urol. 2005; 48: 593-600.
57. Ficarra V, Martignoni G, Maffei N et al. Original and reviewed nuclear grading according to the fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 2005; 103: 68-75.
58. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J. Urol. 2010; 28: 319-27.
59. Furniss D, Harnden P, Ali N et al. Prognostic factors for renal cell carcinoma. Cancer Treat. Rev. 2008; 34: 407-26.
60. de Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am. J. Surg. Pathol. 2001; 25: 275-84.
61. Lam JS, Shvarts O, Said JW et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 2005; 103: 2517-25.
62. Sengupta S, Lohse CM, Leibovich BC et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005; 104: 511-20.
63. Eggener SE, Rubenstein JN, Smith ND et al. Renal tumors in young adults. J. Urol. 2004; 171: 106-10.
64. Siemer S, Hack M, Lehmann J, Becker F, Stockle M. Outcome of renal tumors in young adults. J. Urol. 2006; 175: 1240-3.
65. Denzinger S, Otto W, Burger M et al. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J. Surg. Oncol. 2007; 5: 16.
66. Jung EJ, Lee HJ, Kwak C, Ku JH, Moon KC. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma. Urology 2009; 73: 137-41.
67. Sanchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J. Urol. 2004; 171 (6 Pt 1): 2160-5.
68. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol. Oncol. 2002; 7: 135-40.
69. Schips L, Lipsky K, Zigeuner R et al. Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology 2003; 62: 1024-8.
70. Kim HL, Belldegrun AS, Freitas DG et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J. Urol. 2003; 170: 1742-6.
71. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J. Urol. 2004; 171: 1810-13.
72. Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur. Urol. 2003; 44: 226-32.
73. Patard JJ, Leray E, Cindolo L et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J. Urol. 2004; 172: 858-62.
74. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 2001; 19: 1649-57.
75. Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 2004; 22: 3316-22.
76. Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int. J. Urol. 2004; 11: 364-7.
77. Suppiah R, Shaheen PE, Elson P et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 1793-800.
78. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000; 86: 203-7.
79. Bensalah K, Leray E, Fergelot P et al. Prognostic value of thrombocytosis in renal cell carcinoma. J. Urol. 2006; 175 (3 Pt 1): 859-63.
80. Gogus C, Baltaci S, Filiz E, Elhan A, Beduk Y. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004; 63: 447-50.
81. O'Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J. Urol. 2002; 168 (4 Pt 1): 1378-80.
82. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int. J. Urol. 1998; 5: 418-22.
83. Yasunaga Y, Shin M, Miki T, Okuyama A, Aozasa K. Prognostic factors of renal cell carcinoma: a multivariate analysis. J. Surg. Oncol. 1998; 68: 11-18.
84. Kawai Y, Matsuyama H, Korenaga Y et al. Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. Urol. Int. 2009; 83: 306-10.
85. Magera JS Jr, Leibovich BC, Lohse CM et al. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 2008; 71: 278-82.
86. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand. J. Urol. Nephrol. 2000; 34: 246-51.
87. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2530-40.
88. Karakiewicz PI, Trinh QD, Lam JS et al. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur. Urol. 2007; 52: 1428-36.
89. Johnson TV, Abbasi A, Owen-Smith A et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J. Urol. 2010; 183: 480-5.
90. Johnson TV, Abbasi A, Owen-Smith A et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 2010; 76 (3): 766.
91. Saito K, Tatokoro M, Fujii Y et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur. Urol. 2009; 55: 1145-53.
92. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008; 101: 959-63.
93. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 2006; 94: 781-4.
94. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 2006; 13: 1365-70.
95. Casamassima A, Picciariello M, Quaranta M et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J. Urol. 2005; 173: 52-5.
96. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J. Urol. 1999; 162: 1934-7.
97. Bigot P, Lughezzani G, Karakiewicz P et al. The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality. J. Urol. 2010; 183: 486-91.
98. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur. J. Cancer Prev. 2002; 11: 245-52.
99. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 2000; 163: 343-7.
100. Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the groupe francais d'immunotherapie. J. Clin. Oncol. 2004; 22: 2371-8.
101. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 3317-22.
102. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 2003; 9: 802-11.
103. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol. 2008; 180: 510-13.
104. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 2007; 100: 556-60.
105. Cindolo L, de la Taille A, Messina G et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003; 92: 901-5.
106. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J. Urol. 2008; 179: 2146-51.
107. Sorbellini M, Kattan MW, Snyder ME et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J. Urol. 2005; 173: 48-51.
108. Hupertan V, Roupret M, Poisson JF et al. Low predictive accuracy of the kattan postoperative nomogram for renal cell carcinoma recurrence in a population of french patients. Cancer 2006; 107: 2604-8.
109. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 2002; 20: 4559-66.
110. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 2002; 168: 2395-400.
111. Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol. 2007; 25: 1316-22.
112. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20: 289-96.
113. Kanao K, Mizuno R, Kikuchi E et al. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification. J. Urol. 2009; 181: 480-5.
114. Brookman-Amissah S, Kendel F, Spivak I et al. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. BJU Int. 2009; 103: 1375-80.
115. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol. Clin. North Am. 2008; 35: 613-25.
116. Cindolo L, Patard JJ, Chiodini P et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter european study. Cancer 2005; 104: 1362-71.
117. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 2001; 166: 63-7.
118. Onea C, Mouracade P, Roman H et al. External validation of the university of los angeles integrated staging system (UISS) in localized renal cell carcinoma: single center study. Prog Urol. 2010; 20: 35-9.
119. Fujii Y, Saito K, Iimura Y et al. External validation of the mayo clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J. Urol. 2008; 180: 1290-5.
120. Zigeuner R, Hutterer G, Chromecki T et al. External validation of the mayo clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur. Urol. 2010; 57: 102-9.
121. Ficarra V, Martignoni G, Lohse C et al. External validation of the mayo clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J. Urol. 2006; 175: 1235-9.